Context Therapeutics has reported a 29% response rate in an ovarian cancer study. The company's shares experienced a significant decline, but some analysts view this as an overreaction and see a buying opportunity. It is unclear how the study's results will ultimately impact the company's prospects, with some outlets focusing on the response rate and others on the stock's downturn.